Copyright: ©Author(s) 2026.
World J Gastroenterol. Jan 21, 2027; 33(3): 127331
Published online Jan 21, 2027. doi: 10.3748/wjg.127331
Published online Jan 21, 2027. doi: 10.3748/wjg.127331
Table 1 The demographic and clinical characteristics of the enrolled patients
| Baseline characteristics | VA group | VBAM group | P value |
| Gender (female/male) | 49/43 | 41/51 | 0.238 |
| Age, mean ± SD (years) | 40.86 ± 10.96 | 38.67 ± 9.69 | 0.154 |
| Body mass index, mean ± SD (kg/m2) | 23.55 ± 3.0 | 23.85 ± 3.1 | 0.506 |
| Cigarette smoking (yes/no) | 11/81 | 18/74 | 0.157 |
| Alcohol drinking (yes/no) | 20/72 | 26/66 | 0.307 |
| Family history of gastric cancer (yes/no) | 8/84 | 7/85 | 0.788 |
| Education level ≥ college (yes/no) | 71/21 | 74/18 | 0.588 |
| Dyspeptic symptoms (yes/no) | 29/63 | 31/61 | 0.753 |
| Atrophy (yes/no) | 27/65 | 25/67 | 0.619 |
| Comorbidities (yes/no) | 15/77 | 13/79 | 0.624 |
Table 2 The eradication rates of each group
| Analysis | VA group | VBAM group | 1Rate difference | 2Rate difference | P1 value | P2 value |
| ITT 95%CI | 92.4% (85/92) (85.1%-96.3%) | 91.3% (84/92) (83.8%-95.5%) | 1.1% (-6.8% to 9.0%) | 1.1% (-7.3% to 9.6%) | 0.788 | 0.003 |
| mITT 95%CI | 95.5% (85/89) (89.0%-98.2%) | 96.6% (84/87) (90.4%-98.8%) | -1.1% (-6.8% to 4.7%) | -1.1% (-7.9%-5.7%) | 0.722 | 0.001 |
| PP 95%CI | 95.4% (83/87) (88.8%-98.2%) | 96.4% (81/84) (90.0%-98.8%) | -1.0% (-7.0% to 4.9%) | -1.0% (-8.1%-6.0%) | 0.734 | 0.002 |
Table 3 Adverse events in each group, n (%)
| Safety and adherence | VA group | VBAM group | Risk ratio (95%CI) | P value |
| Total adverse events | 17 (18.5) | 24 (26.1) | 0.71 (0.41-1.23) | 0.215 |
| Mild/moderate/severe | 13/4/0 | 17/7/0 | N/A | 0.736 |
| Dysgeusia | 2 (2.2) | 3 (3.3) | 0.67 (0.11-3.90) | 1.000 |
| Nausea or anorexia | 5 (5.4) | 5 (5.4) | 1.00 (0.30-3.34) | 1.000 |
| Abdominal discomfort | 6 (6.5) | 11 (12.0) | 0.55 (0.21-1.41) | 0.203 |
| Diarrhea | 4 (4.3) | 8 (8.7) | 0.50 (0.16-1.60) | 0.370 |
| Constipation | 2 (2.2) | 1 (1.1) | 2.00 (0.18-21.67) | 1.000 |
| Fatigue | 1 (1.1) | 3 (3.3) | 0.33 (0.04-3.15) | 0.613 |
| Headache | 2 (2.2) | 2 (2.2) | 1.00 (0.14-6.95) | 1.000 |
| Dizziness | 1 (1.1) | 9 (9.8) | 0.11 (0.01-0.86) | 0.023 |
| Skin rash | 2 (2.2) | 1 (1.1) | 2.00 (0.18-21.67) | 1.000 |
| Others | 2 (2.2) | 3 (3.3) | 0.67 (0.11-3.90) | 1.000 |
| Adherence | 87 (94.6) | 84 (91.3) | 1.04 (0.96-1.12) | 0.388 |
Table 4 Cost-effectiveness analysis of each group from a healthcare payer perspective
| Cost item | VA group (n = 92) | VBAM group (n = 92) |
| Drug cost (CNY) | 301.40 | 477.90 |
| Examination cost (CNY) | 145.11 | 141.84 |
| Adverse events-related cost (CNY) | 2.53 | 4.84 |
| Total cost per patient (CNY) | 449.04 | 624.58 |
| Effectiveness (%) | 92.4 | 91.3 |
| CER (CNY per successfully eradicated patient) | 485.97 | 684.10 |
| ICER (CNY per additional successfully eradicated patient) | -15958.18 | - |
- Citation: Chen JH, Liu XW, Xu YT, Wang N, Guo JF, Chen LY, Gao FS, Zhang C. Randomized trial of vonoprazan dual therapy vs bismuth-containing quadruple therapy with two low-resistance antibiotics for Helicobacter pylori eradication. World J Gastroenterol 2027; 33(3): 127331
- URL: https://www.wjgnet.com/1007-9327/full/v33/i3/127331.htm
- DOI: https://dx.doi.org/10.3748/wjg.127331